Background
Methods
Statistical analysis
Results
Patient characteristics
Control group | 1–4 g FC | 5–9 g FC | ≥10 g FC |
P-valuea
| |
---|---|---|---|---|---|
(n = 193) | (n = 97) | (n = 93) | (n = 52) | ||
Age, years | 50 (37–65) | 40 (22–56) | 41 (26.5–53) | 43.5 (28–53.75) | <0.0001 |
Male, n (%) | 153 (79.3) | 69 (71.1) | 75 (80.6) | 39 (75.0) | 0.3513 |
ISS | 22 (17–27.5) | 29 (25–40) | 34 (23–45) | 41.5 (33.25–50) | <0.0001 |
Mortality, n (%) | 12 (6.2) | 4 (4.1) | 5 (5.4) | 8 (15.4) | 0.0533 |
Massive transfusion, n (%) | 1 (0.5) | 8 (8.2) | 26 (28.0) | 45 (86.5) | <0.0001 |
FC, g | – | 3 (2–4) | 6 (6–8) | 12 (10.25–15.75) | <0.0001 |
RBC | |||||
units (total) | 0 (0–0) | 3 (2–6) | 7 (5–10) | 15 (11.35–20.75) | <0.0001 |
n (%) | 25 (13.0) | 74 (76.3) | 87 (93.5) | 52 (100) | <0.0001 |
unitsb
| 3 (2–4.5) | 4.5 (3–7) | 7.0 (5–10) | 15.0 (11.25–20.75) | <0.0001 |
PCC | |||||
IU (total) | 0 (0–0) | 0 (0–0) | 300 (0–1800) | 3600 (1800–5400) | <0.0001 |
n (%) | 5 (2.6) | 22 (22.7) | 46 (49.5) | 50 (96.2) | <0.0001 |
IUb
| 1800 (1200–4500) | 1200 (1150–1800) | 1800 (1425–2400) | 3600 (1800–5425) | <0.0001 |
Platelet concentrate | |||||
units (total) | – | 0 (0–0) | 0 (0–0) | 1 (0–2) | <0.0001 |
n (%) | – | 1 (1.0) | 17 (18.2) | 28 (53.8) | <0.0001 |
unitsb
| – | 2 (2–2) | 2 (1.5–2.0) | 2.0 (2.0–3.75) | 0.2441 |
FFP | |||||
units (total) | – | – | 0 (0–0) | 0 (0–0) | <0.0001 |
n (%) | – | – | 3 (3.2) | 10 (19.2) | <0.0001 |
unitsb
| – | – | 5 (5–8) | 10 (10–13) | 0.0097 |
Time course of laboratory parameters in the control and treatment groups
ER | Day 1 | Day 2 | Day 3 | Day 4 | Day 5 | Day 6 | Day 7 | |
---|---|---|---|---|---|---|---|---|
Fibrinogen (g/l) | ||||||||
Treatment | 1.58 (1.07–2.03) | 2.33 (2.02–2.71) | 4.15 (3.47–4.83) | 5.51 (4.72–6.7) | 6.12 (5.12–7.54) | 6.55 (5.3–7.9) | 6.8 (5.41–8.19) | 6.99 (5.9–8.49) |
n
| 242 | 242 | 238 | 239 | 231 | 227 | 224 | 207 |
Control | 2.46 (2–2.98) | 2.75 (2.25–3.25) | 4.36 (3.77–5.32) | 5.74 (4.74–6.74) | 6.23 (5.07–7.64) | 6.67 (5.25–7.9) | 6.95 (5.56–8.24) | 7 (5.59–8.45) |
n
| 191 | 174 | 169 | 150 | 149 | 145 | 147 | 139 |
P-value | <0.0001 | <0.0001 | 0.0034 | 0.2122 | 0.9996 | 0.6106 | 0.6995 | 0.6602 |
PTI (%) | ||||||||
Treatment | 66 (54–78.5) | 60 (49–69) | 60 (51–72) | 73 (63–86) | 82 (69–93) | 84 (70–99) | 87.5 (73–98) | 87 (77–98) |
n
| 241 | 242 | 238 | 238 | 231 | 227 | 224 | 207 |
Control | 90 (78–101) | 75 (64–85) | 78 (64–87) | 82 (70–94) | 89 (76.5–99) | 92 (79–101) | 94 (84–104) | 92 (81–103) |
n
| 192 | 175 | 169 | 150 | 149 | 145 | 147 | 140 |
P-value | <0.0001 | <0.0001 | <0.0001 | <0.0001 | 0.0009 | 0.0012 | <0.0001 | 0.0038 |
aPTT (s) | ||||||||
Treatment | 30 (26.2–36.4) | 39.5 (35.4–45.3) | 39.7 (35.5–45.2) | 38.3 (34.2–43.5) | 36.1 (32–40.8) | 34.3 (30.9–39.1) | 33.2 (30–37.7) | 32.3 (29.3–37.2) |
n
| 237 | 238 | 234 | 236 | 231 | 227 | 224 | 208 |
Control | 26.6 (24.1–28.9) | 32.6 (30–36.6) | 35 (31.6–38.3) | 34.1 (31.5–38) | 33 (29.7–36.3) | 31.3 (28.9–35.5) | 30.5 (28–34.4) | 30 (27.4–33.3) |
n
| 192 | 175 | 168 | 149 | 149 | 145 | 147 | 140 |
P-value | <0.0001 | <0.0001 | <0.0001 | <0.0001 | <0.0001 | <0.0001 | <0.0001 | <0.0001 |
AT-III (%) | ||||||||
Treatment | 73 (61–86) | 57 (46.3–66) | 57 (46.8–68) | 57.5 (48–68.8) | 64 (53–75) | 71 (60–86) | 82 (64–96) | 89.5 (75–103) |
n
| 103 | 204 | 182 | 164 | 152 | 131 | 119 | 116 |
Control | 88 (77–97) | 74.5 (65.3–84) | 75 (64–85) | 76 (60.5–84) | 85 (72–96.5) | 90 (72.5–102.5) | 98 (85–108.5) | 100 (89.8–111.3) |
n
| 115 | 132 | 99 | 78 | 73 | 85 | 82 | 70 |
P-value | <0.0001 | <0.0001 | <0.0001 | <0.0001 | <0.0001 | <0.0001 | <0.0001 | 0.0010 |
Platelet count (×109/l) | ||||||||
Treatment | 184 (143–230) | 96 (64.8–134.3) | 91.5 (64.8–117) | 92 (65.5–120) | 111.5 (76–144) | 134 (94–174) | 160 (116.8–209) | 205 (158–266) |
n
| 241 | 242 | 242 | 241 | 238 | 237 | 238 | 229 |
Control | 222 (174–262) | 158 (130–189.5) | 141 (109–175) | 143 (109–175) | 160 (130–200.5) | 184 (155–224.8) | 209 (171.5–250) | 240 (197–295) |
n
| 193 | 185 | 185 | 179 | 178 | 180 | 173 | 163 |
P-value | <0.0001 | <0.0001 | <0.0001 | <0.0001 | <0.0001 | <0.0001 | <0.0001 | <0.0001 |
Haemoglobin (g/l) | ||||||||
Treatment | 110 (90–127) | 90 (82–102) | 90 (80–98) | 88 (80–97) | 90 (81–98) | 90 (82–98) | 91 (84–99) | 90 (81–97) |
n
| 242 | 242 | 242 | 242 | 241 | 238 | 238 | 232 |
Control | 132 (118–142) | 100 (90–111) | 93 (84–109) | 92 (82–106) | 93 (84–104) | 94 (85–105) | 95 (86–106) | 94 (87–106) |
n
| 193 | 187 | 190 | 184 | 184 | 185 | 178 | 166 |
P-value | <0.0001 | <0.0001 | 0.0004 | 0.0008 | 0.0103 | 0.0005 | 0.0013 | <0.0001 |
White Blood Cell count (×109/l) | ||||||||
Treatment | 13.1 (10–17.7) | 7.1 (5.5–9.4) | 8.6 (6.5–10.4) | 7.9 (6.1–9.9) | 7.4 (5.7–9.9) | 7.9 (6.1–10.3) | 9 (7.3–11.4) | 10.2 (8–12.9) |
n
| 178 | 203 | 205 | 203 | 201 | 201 | 204 | 202 |
Control | 13.3 (10.8–17.3) | 8.2 (6.4–9.9) | 8.1 (6.7–9.9) | 7.3 (6–9.6) | 7.2 (5.6–9.3) | 8 (6.3–9.9) | 9.3 (7–11.1) | 9.6 (7.3–11.7) |
n
| 129 | 131 | 129 | 128 | 127 | 128 | 127 | 125 |
P-value | 0.8283 | 0.0123 | 0.5443 | 0.4120 | 0.3542 | 0.9782 | 0.9680 | 0.0819 |
CRP (mg/l) | ||||||||
Treatment | N/A | 70 (39.5–95.5) | 174 (135.5–224.5) | 182 (128–236.5) | 174 (104–228) | 145 (88.8–213.3) | 131.5 (80.5–207.3) | 143 (89–211) |
n
| 217 | 197 | 194 | 206 | 202 | 198 | 185 | |
Control | N/A | 58 (34.5–88.5) | 147 (97.9–204) | 145 (91–221.5) | 130 (82.1–237.5) | 113 (75.5–195) | 94 (55.5–161) | 92.9 (46.2–147.5) |
n
| 126 | 116 | 134 | 125 | 133 | 133 | 121 | |
P-value | 0.0989 | 0.0015 | 0.0006 | 0.0788 | 0.0392 | 0.0010 | <0.0001 | |
IL-6 (pg/ml) | ||||||||
Treatment | 165 (86–422) | 458 (209–1276) | 261 (131–702) | 175 (93–413) | 130 (55–243) | 133 (57–249) | 116 (68–224) | 79 (50–120) |
n
| 96 | 91 | 82 | 78 | 80 | 67 | 74 | 69 |
Control | 67 (28–144) | 103 (58–284) | 78 (40–240) | 93 (43–258) | 61 (31–122) | 65 (30–134) | 44 (25–82) | 39 (21–77) |
n
| 103 | 61 | 51 | 50 | 52 | 49 | 57 | 47 |
P-value | <0.0001 | <0.0001 | <0.0001 | 0.0012 | 0.0010 | 0.0005 | <0.0001 | 0.0003 |
PCT (ng/ml) | ||||||||
Treatment | N/A | 2.2 (0.7–6) | 2 (0.7–7.8) | 1.3 (0.5–6) | 1 (0.1–3) | 0.7 (0.4–2.3) | 0.5 (0.2–2) | 0.5 (0.1–1.3) |
n
| 50 | 63 | 75 | 93 | 90 | 83 | 95 | |
Control | N/A | 0.5 (0.2–1.5) | 0.4 (0.1–1.8) | 0.3 (0.2–1.3) | 0.3 (0.2–1.3) | 0.3 (0.1–0.7) | 0.2 (0.1–0.5) | 0.2 (0.1–0.4) |
n
| 53 | 60 | 53 | 62 | 62 | 65 | 66 | |
P-value | <0.0001 | <0.0001 | 0.0001 | 0.0607 | <0.0001 | <0.0001 | 0.0006 |
Plasma fibrinogen levels
Other coagulation tests
Haematological and inflammatory parameters
Subgroup analyses
Plasma fibrinogen levels of subgroups
Standard coagulation tests of subgroups
Haematological parameters of subgroups
Inflammatory markers of subgroups
Discussion
Conclusions
Key messages
-
It has been questioned whether fibrinogen concentrate (FC) therapy has the potential to abnormally increase plasma fibrinogen levels thus leading to a prothrombotic risk following trauma
-
In this retrospective study, trauma patients receiving FC therapywere compared with patients not receiving FC
-
Patients treated with FC had higher injury severity scores and higher transfusion of allogeneic blood products than those not receiving FC, butplasma fibrinogen levels from day 3 to day 7 post-trauma were similar in the two patient groups, reaching a plateau of ~7 g/l between day 5 and day 7
-
These data show that FC therapy does not lead to higher plasma fibrinogen levels among trauma patients